NCT03611686

Brief Summary

Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
219

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 17, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 26, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 2, 2018

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

March 24, 2025

Status Verified

March 1, 2025

Enrollment Period

8 years

First QC Date

July 26, 2018

Last Update Submit

March 19, 2025

Conditions

Metastatic Prostate Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

  • Number of alive patient

    3 years

Secondary Outcomes (1)

  • Number of alive patient disease free

    3 years

Study Arms (1)

patient followed for metastatic prostate adenocarcinoma

patient wil be followed for metastatic prostate adenocarcinoma during 3 years

Drug: Local chemotherapy

Interventions

Local chemotherapyDRUG

Local chemotherapy will be administrated according to local recommendation

patient followed for metastatic prostate adenocarcinoma

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with metastatic prostate adenocarcinoma resistant to castration

You may qualify if:

  • Patient monitored for castration-resistant metastatic prostate
  • Patients starting a first or second line treatment as part of castration resistance
  • Patient not objecting to the study after reading the information letter
  • Patient aged over 18 years

You may not qualify if:

  • Patient monitored for non-metastatic prostate cancer
  • Patient monitored for castration-nonresistant prostate cancer
  • Patient not able to understand the information letter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rouen University Hospital

Rouen, France

Location

Study Officials

  • Christian PFISTER

    University Hospital, Rouen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2018

First Posted

August 2, 2018

Study Start

April 17, 2018

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

March 24, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)